Aim: Dyslipidemia is the most common lipid metabolism disorder in humans, and its etiology remains elusive. Hypertriglyceridemia (HTG) is a type of dyslipidemia that contributes to atherosclerosis and coronary heart disease. Previous studies have demonstrated that mutations in lipoprotein lipase (LPL), apolipoprotein CII (APOC2), apolipoprotein AV (APOA5), glycosylphosphatidylinositol anchored high-density lipoprotein-binding protein 1 (GPIHBP1), lipase maturation factor 1 (LMF1), and glycerol-3 phosphate dehydrogenase 1 (GPD1) are responsible for HTG by using genomic microarrays and next-generation sequencing. The aim of this study was to identify genetic lesions in patients with HTG.
Introduction
Severe hypertriglyceridemia (HTG) is a disorder characterized by elevated plasma triglyceride levels of 885 mg/dL (10.0 mmol/L) 1) or 1000 mg/dL (11.2 mmol/L) 2) and could lead to chylomicronemia
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Materials and Methods

Patients
In this study, a family of seven members from Jiangsu province across three generations, which was admitted to the Affiliated Hospital of Yangzhou University, 2017 (Yangzhou, China), was included (Fig. 1A, Table 1 ). The proband was diagnosed with severe HTG with a plasma triglyceride level of 38.70 mmol/L. No severe HTG was present in the other family members. The present study was approved by the Ethics Committee of Yangzhou University (Yangzhou, China). All subjects provided consent prior to the commencement of the study.
DNA Extraction
Genomic DNA was extracted from the peripheral blood of the proband and other family members by using a DNeasy Blood and Tissue kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer's protocol, on the QIAcube automated DNA extraction robot (Qiagen, Inc.).
Mutation Sequencing
Several genes were amplified by polymerase chain reaction (PCR), including LMF1 (Refseq: NM_022773), LPL (Refseq: NM_000237), APOC2 (Refseq: NM_ 001646), APOA5 (Refseq: NM_052968), GPD1 (Refseq: NM_005276), and GPIHBP1 (Refseq: NM_ 178172). PCR was performed using 25-µL reaction volumes, containing 0.3-mM dNTPs, 1X PCR buffer (10-mM Tris-HCl, pH 9.0; 50-mM KCl; 0.1% Triton X-100; and 0.01% w/v gelatin), 2.0-mM MgCl2, 0.5 µM of each primer, 1.5 U of Taq polymerase (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and 50 ng of genomic DNA. Thermocycling conditions were as follows: Initial denaturation at 95 for 5 min, followed by 35 cycles of amplification consisting of denaturation at 95 for 30 sec, annealing at 55 -61 for 30 sec, and extension at 72 for 1 min. A final extension step was performed at 72 for 7 min. The sequences of the PCR products were obtained using the ABI 3100 genetic analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers are supplied in Supplementary Table 1 .
Bioinformatics Analysis and Mutation Prediction
Multiple LMF1 protein sequences were aligned in several species (version 3.6; http://www.ncbi.nlm. nih.gov). Polymorphism Phenotyping-2 21) , Sorting Intolerant From Tolerant 22) , and MutationTaster 23) were used to predict the effects of these sequence variants on the function of LMF1 protein.
Severe HTG is mainly divided into primary and secondary types. The common causes of secondary HTG are renal failure, nephrotic syndrome, diabetes mellitus, hypothyroidism, excessive alcohol or drug use, and some rare endocrine and metabolic disorders 9, 10) . Primary or genetic HTG with a monogenic etiology is less common and is characterized by the accumulation of TG-rich lipoproteins (chylomicrons, very low-density lipoprotein, and remnant lipoproteins) in the plasma [11] [12] [13] . These patients are usually carriers of homozygous or compound heterozygous loss-of-function mutations of genes for HTG, including LPL, APOC2, APOA5, GPIHBP1, LMF1, and GPD1.
LPL, a principal enzyme in plasma lipid metabolism, is synthesized in the endoplasmic reticulum (ER) of parenchymal cells in muscle and adipose tissue 14, 15) . It is the rate-limiting enzyme in tissues that hydrolyzes triglycerides in chylomicrons and very low-density lipoprotein (VLDL) and thereby makes fatty acids available for tissue metabolism 15) . Meanwhile, macrophage foam cell formation is associated with triglyceride-rich lipoprotein (TGRL)-LPL-VLDL receptor pathway, which is a critical step in the initial stages of atherosclerotic process 16) . As a result, the activity of LPL is a key determinant of tissue lipid partitioning and plasma TG clearance. LPL deficiency results in elevated plasma TGs 17) . In adipocytes, lipase maturation is the conversion of the newly synthesized LPL into a catalytically active enzyme, which involves glycosylation, glycan processing, folding, and the assembly of homodimers 18) . LMF1 encodes a transmembrane protein chaperone localized to the ER membrane that is involved in the maturation of LPL and hepatic lipase (HL) 19, 20) . Patients with deleterious mutation in LMF1 also show combined lipase deficiency (cld) with concomitant HTG and associated disorders 17) . According to the Human Gene Mutation Database, there are only 14 mutations that have been identified in previous mutation screenings of LMF1 in patients with familial or sporadic HTG. In the present study, a compound heterozygous mutation (c.257C T/p.P86L and c.1184C T/p.T395I) in exons 2 and 8 of LMF1 was identified and co-segregated with the affected patient in this family. Both mutations were first reported worldwide. Bioinformatics analysis predicted that both mutations were deleterious. Neither of them has been presented in the single nucleotide polymorphism (dbSNP) databases (https://www.ncbi. nlm.nih.gov/projects/SNP/) and Exome Variant Server databases (http://evs.gs.washington.edu/EVS/). independent tests. The data were analyzed by unpaired two-tailed tests using Graph Pad Prism V.5 software (V.5.0).
Result
Clinical Case
We reported a case of a 51-year-old man who was hospitalized for mild left-sided hemiplegia (Fig.1A, Table 1 ). Magnetic resonance imaging confirmed the diagnosis of lacunar infarction. Lipid profile assessment revealed the presence of HTG (TG, 38.70 mmol/L). His body mass index was 24.7 kg/m 2 .
LPL and HL Assays
We measured the pre-heparin and post-heparin LPL and HL activity. Blood samples were collected from the proband and his brother (II-3) after an overnight fast. Their blood was collected again 15 min after an intravenous bolus injection of heparin (100 IU/kg). His brother was set as a normal control for triglyceride. LPL and HL activity assays of other family members were not performed because they refused to receive heparin. LPL and HL activities were measured as previously described 24) . LPL and HL activities were detected by LPL Activity Assay Kit (Sigma, Roar Biomedical Inc.). Each assay was performed in three leucine in LMF1. The maximum frequency values (MAF) of both mutations in Exome Aggregation Consortium and TGP (1000 genomes project) database were less than 0.001. Both mutations were not found in our 200 control cohorts, as well as in dbSNP and Exome Variant Server database . The amino acid sequences of LMF1 were found to be aligned in humans, rhesus monkeys, mice, dogs, chicken, and zebrafishes, which revealed that the affected amino acids were evolutionarily conserved (Fig. 1C) . The two variants were probably damaging (c.257C T/p. P86L) and possibly damaging (c.1184C T/p.T395I) in Polyphen-2, were both damaging in SIFT, and were disease causing in MutationTaste. The uniformity among the detrimental effects of the variants as predicted by all these bioinformatics programs suggested that these mutations are important in the function of LMF1.
LPL and HL Activities
We measured the post-heparin LPL and HL activities of the proband and a normal plasma triglyceride family member (II3) as a control. The levels of the plasma post-heparin LPL and HL activities in the proband (57 and 177 mU/mL) were reduced to 24% and 75%, respectively, compared with those assayed in the normal plasma triglyceride control (Fig. 2) .
He had a history of pancreatitis, but did not have a history of diabetes, hypertension, smoking, or alcohol abuse. However, he had a family history of cardiovascular disease: His father had died of coronary heart disease at the age of 70 years. Secondary causes of severe HTG were ruled out. An impaired glucose tolerance was indicated by an HbA1c of 5.6%. Doppler ultrasound showed that he had atherosclerotic changes with plaques in the right internal carotid artery. Diffusion-weighted imaging showed lacunar infarction of right basal ganglia, while magnetic resonance angiography showed multiple intracranial vascular stenosis. Another three family members showed the HTG phenotype, but the levels of TG were not very high ( Table  1) .
Molecular Genetic Analysis
The possibility of HTG induction by known genes was investigated. Two missense mutations (c.257C T/p.P86L and c.1184C T/p.T395I) in LMF1 were identified by using Sanger sequencing, and they were co-segregated with the affected members (Fig. 1B) . The allelic segregation analysis revealed that the c.1184C T/p.T395I mutation was carried by the mother, whereas the c.257C T/p.P86L mutation was speculated to be inherited from the father. These two novel mutations (c.257C T/p.P86L and c.1184C T/p.T395I) caused a substitution of proline by leucine and a substitution of threonine by iso- 17, 25) . Our study also demonstrated that lipase activities, especially the LPL activity, in the proband decreased significantly.
Previous studies revealed that LMF1 is a multipass transmembrane protein of the ER that has five transmembrane domains, with its three soluble domains and C-terminus in the ER lumen and N-terminus in the cytosol. The loops (labeled A-D) connect all these domains (Fig. 3B) . This subcellular structure is consistent with the post-translational effect of LMF1 for the maturation of lipases, as these enzymes attain catalytic activity within the ER 28, 29) . It is also demonstrated that the loop C and the C-terminus of LMF1 are important for dimeric lipase maturation 30) . Indeed, two nonsense mutations (Y439X and W464X) in the C-terminal ER domain of LMF1 resulted in truncated variants 17, 25) . In both cases, severe HTG were associated with deficiency for lipase maturation. In the present study, these two mutations are both located in the ER lumen. The novel mutation (c.257C T/p.P86L) located in loop-A domain resulted in the substitution of proline by leucine. The loop-A domain of LMF1 is a part of lipase-binding domain and plays a crucial role in activating lipase activity 19, 30, 31) . Another novel mutation (c.1184C T/p.T395I) located in the highly conserved C-termi-
Discussion
In this study, we report a severe HTG patient with mild stroke associated with a compound heterozygous mutation (c.257C T/p.P86L and c.1184C T/p.T395I) in exons 2 and 8 of LMF1. Our study is consistent with the previous reports that only homozygous and compound heterozygous mutations in LMF1 are responsible for HTG 17, 25) . At the same time, we found that the LPL and HL activities were lower in the proband than in the healthy subject. At present, 14 point mutations of LMF1 have been reported in HTG patients (Fig. 3A) . The outcome of the molecular genetic investigations performed in the present study was consistent with previous studies 17, 25) , which indicated that mutations in LMF1 could cause HTG due to the decreasing activities of LPL and HL.
Combined lipase deficiency (cld) is a recessive mutation located on mouse chromosome 17 that exhibits severely deficient LPL activity 26) . Homozygous cld mutant mice develop extreme HTG as a result of severe deficiency in plasma LPL and HL activities and die within 48 hours or a few days after birth 26, 27) . The precise genetic location of LMF1, which encodes an ER-resident, transmembrane protein containing cld, has been identified 17) . LMF1 plays a critical role in the post-translational maturation of The levels of the plasma post-heparin LPL and HL activity in the proband (57 and 177 mU/mL) were reduced to 24% and 75%, respectively, compared with those assayed in the normal plasma triglyceride control.
that can produce enormous amounts of data and allow analysis of genes in a short period of time, easily and relatively economically 34) . Differential therapeutic strategies may be developed by unraveling the underlying molecular "defect." In the last decades, different types of vectors have been used in clinical trials for treating several monogenetic disorders. A recent study showed that LPL gene therapy had been used successfully in patients with genetic LPL deficiency, and the follow-up study is ongoing to definitively confirm the long-term benefit and safety of this approach 35) . However, there are currently no clear treatment options for LMF1 deficiency. Currently, only one research has reported that fibrate drug combination therapy insulin may decrease the level of TG in patients with LMF1 mutation 25) . Fibrates are widely used clinically to treat HTG. They activate peroxisome proliferatoractivated receptors (PPARs), especially PPAR . PPARs can modulate fat metabolism and adipose tissue differentiation. They can further upregulate the transcription of multiple genes that facilitate lipid metabolism, such as apolipoprotein (apo) A-5 and LPL, and downregulate the transcription of apoC-3. However, fibrates have less selectivity for PPAR and are associated with a high risk of side effects 36) . Recently, K-877 nus domain, which is also part of the lipase maturation domain, contributes to the maturation of lipase. Consequently, they may both affect the function of LMF1, further down-regulate the activities of LPL and HL and lead to HTG.
Previous studies have confirmed that nonsense mutation of LMF1 affects the activity of lipoprotein lipase and can cause HTG 17, 25) . Patients carrying p.Y439X mutation showed severe HTG, recurrent episodes of pancreatitis, and diabetes mellitus. However, another patient harboring p.W464X mutation only presented HTG 17) . The differences indicated that mutations in LMF1 may show high genetic heterogeneity and complexity in a diverse genetic architecture 32, 33) . In-depth diagnostic strategies of HTG are not routinely used in clinical works due to the costs of genetic analysis and the low prevalence of severe HTG. In this study, we have shown that a molecular diagnosis is feasible and effective in carefully selected patients with severe HTG. Fortunately, a highly accurate customized generation sequencing (NGS) panel for targeted gene sequencing of 18 genes involved in HTG has been recently developed, which offers the possibility to perform massively parallel sequencing (Pemafibrate) has been shown to have higher PPAR agonistic activity and selectivity than fibrates 37) . In a recent study, Sairyo et al. used K-877 to treat a mouse model with diet-induced HTG. The result revealed that K-877 and fenofibrate could both increase the activity of LPL and decrease the level of serum TG. Moreover, K-877 may attenuate postprandial HTG more effectively than fenofibrate by suppressing the postprandial increase of chylomicrons and the accumulation of chylomicron remnants 38) . In our subsequent work, we plan to treat our patient with K-877. We hope this measure can decrease the TG level of the proband and provide more acute therapy examples for clinic.
In conclusion, the present study identified an LMF1 compound heterozygous mutation (c.257C T/p.P86L and c.1184C T/p.T395I) in a patient with severe HTG. To the best of our knowledge, this is the first report of these two mutations worldwide. The results of the present study offer further support for the significant involvement of LMF1 in severe HTG. The results also expand on the spectrum of LMF1 mutations and contribute to the genetic diagnosis and counseling of families with severe HTG.
